EW241220P57500
- 0.10
- 0.000.00%
Edwards Lifesciences Newsroom
Deutsche Bank Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $85
Deutsche Bank Sticks to Its Buy Rating for Edwards Lifesciences (EW)
Baird Adjusts Edwards Lifesciences Price Target to $70 From $68, Maintains Neutral Rating
Morgan Stanley Downgrades Edwards Lifesciences(EW.US) to Sell Rating, Cuts Target Price to $46
Edwards Lifesciences: Competitive Pressures and Valuation Concerns Lead to Sell Rating
Bernstein Downgrades Edwards Lifesciences(EW.US) to Sell Rating, Announces Target Price $73
BofA Securities Upgrades Edwards Lifesciences(EW.US) to Buy Rating, Raises Target Price to $90
BofA Securities Upgrades Edwards Lifesciences to Buy From Neutral, Price Target Is $90
Edwards Lifesciences Analyst Ratings
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $83
Truist Financial Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $78
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $75 to $90
Oppenheimer Remains a Buy on Edwards Lifesciences (EW)
Edwards Lifesciences (EW) Receives a Buy From RBC Capital
Bank of America Securities Keeps Their Hold Rating on Edwards Lifesciences (EW)
Hold Rating for Edwards Lifesciences: Balancing Risks and Opportunities Amidst Market Variability
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Evolent Health (EVH) and Palisade Bio (PALI)
Edwards Lifesciences Is Maintained at Hold by Canaccord Genuity
Edwards Lifesciences Analyst Ratings
Mizuho Adjusts Price Target on Edwards Lifesciences to $85 From $78, Keeps Outperform Rating